Recursion Pharmaceuticals Q3 EPS $(0.43) Misses $(0.39) Estimate, Sales $10.53M Miss $12.87M Estimate
Portfolio Pulse from Benzinga Newsdesk
Recursion Pharmaceuticals (NASDAQ:RXRX) reported Q3 losses of $(0.43) per share, missing the analyst consensus estimate of $(0.39) by 10.26%. This is a 22.86% decrease from the same period last year. The company also reported quarterly sales of $10.53 million, missing the analyst consensus estimate of $12.87 million by 18.16%, a 19.96% decrease from the same period last year.
November 09, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Recursion Pharmaceuticals reported lower than expected Q3 earnings and sales, indicating a potential negative impact on its stock price.
Recursion Pharmaceuticals reported a larger than expected loss and lower than expected sales for Q3. This underperformance could negatively impact investor sentiment and lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100